Dr Reddy's Laboratories rose 2.04% at Rs 4,300 at 9:27 IST on BSE after consolidated net profit rose 26% to Rs 720 crore on 11% growth in revenue to Rs 3990 crore in Q2 September 2015 over Q2 September 2014.
The result was announced after market hours yesterday, 29 October 2015.
Meanwhile, the S&P BSE Sensex was up 33.88 points or 0.13% at 26,872.02.
On BSE, so far 11,000 shares were traded in the counter as against average daily volume of 8,733 shares in the past two weeks.
The stock hit a high of Rs 4,312 and a low of Rs 4,232.55 so far during the day.
In constant currency terms, Dr Reddy's Laboratories' revenue grew 14% in Q2 September 2015 over Q2 September 2014. Earnings before interest, taxation, depreciation and amortization (EBITDA) rose 31% to Rs 1140 crore in Q2 September 2015 over Q2 September 2014.
More From This Section
Dr Reddy's Laboratories is an integrated global pharmaceutical company. Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products - Dr Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations.
Powered by Capital Market - Live News